DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Mount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatment
The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a $4 million grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease (SCD) in individuals who do not have asthma. The IMPROVE 2 study is a one-year randomized, placebo-controlled trial involving 80 SCD patients.
According to the U.S. Centers for Disease Control and Prevention, SCD affects 100,000 Americans and is more prevalent in certain ethnic groups, such as African Americans and Hispanic Americans. The Healthcare Cost and Utilization Project, a database consortium sponsored by the federal government, reports that per-patient health care costs in the U.S. are higher for SCD than any other disease, with total expenditures exceeding $2.4 billion.
+myBinderRelated Content
-
news & eventsClinical trial offers hope to adults with sickle cell diseaseAt 33, Alexis Jones-Heggs has known a li...
-
news & eventsVoxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
-
news & eventsEmmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
education & researchThe first two years of life in sickle cell anemia infants: A results of a comprehensive longitudinal studyInfancy is a critical time during which ...
-
education & researchAddressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and...BACKGROUND/AIMS: Neuropathic pain is a k...
-
news & eventsBluebird Bio Presents Data From LentiGlobin Gene Therapy TrialBluebird Bio’s investigational gene th...
-
news & eventsNew Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.